Gilead Sciences, Inc.
GILDGilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Drugs in Pipeline
215
Phase 3 Programs
114
Upcoming Catalysts
23
Next Catalyst
Feb 15, 2026
7dMarket Overview
Stock performance and market intelligence
23 upcoming, 1 past
Brexucabtagene Autoleucel (KTE-X19) Phase 2 Results Expected
Primary completion for Brexucabtagene Autoleucel (KTE-X19) trial (NCT02625480) in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
SourcePembrolizumab Phase 2 Results Expected
Primary completion for Pembrolizumab trial (NCT05186974) in Non-small Cell Lung Cancer
SourceSacituzumab Govitecan-hziy (SG) Phase 2 Results Expected
Primary completion for Sacituzumab Govitecan-hziy (SG) trial (NCT05186974) in Non-small Cell Lung Cancer
SourceGS-1427 Phase 2 Results Expected
Primary completion for GS-1427 trial (NCT06290934) in Ulcerative Colitis
SourcePlacebo Phase 2 Results Expected
Primary completion for Placebo trial (NCT06029972) in Ulcerative Colitis
SourceTilpisertib Fosmecarbil Phase 2 Results Expected
Primary completion for Tilpisertib Fosmecarbil trial (NCT06029972) in Ulcerative Colitis
SourceB/F/TAF Phase 3 Results Expected
Primary completion for B/F/TAF trial (NCT06630286) in HIV-1-infection
SourcePTM B/F/TAF Phase 3 Results Expected
Primary completion for PTM B/F/TAF trial (NCT06630286) in HIV-1-infection
SourceISL/LEN Phase 3 Results Expected
Primary completion for ISL/LEN trial (NCT06630299) in HIV-1-Infection
SourceLenacapavir Injection Phase 2 Results Expected
Primary completion for Lenacapavir Injection trial (NCT06513312) in Pre-Exposure Prophylaxis of HIV Infection
SourceSacituzumab Govitecan-hziy Phase 2 Results Expected
Primary completion for Sacituzumab Govitecan-hziy trial (NCT05101096) in Advanced Solid Tumor
SourceEmtricitabine/tenofovir disoproxil fumarate (F/TDF) Phase 2 Results Expected
Primary completion for Emtricitabine/tenofovir disoproxil fumarate (F/TDF) trial (NCT06513312) in Pre-Exposure Prophylaxis of HIV Infection
SourceSeladelpar 10 mg Phase 3 Results Expected
Primary completion for Seladelpar 10 mg trial (NCT06060665) in Primary Biliary Cholangitis
SourceEmtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Phase 2 Results Expected
Primary completion for Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) trial (NCT06101329) in Pre-Exposure Prophylaxis of HIV Infection
SourceLenacapavir Injection Phase 2 Results Expected
Primary completion for Lenacapavir Injection trial (NCT06101329) in Pre-Exposure Prophylaxis of HIV Infection
SourceDomvanalimab Phase 2 Results Expected
Primary completion for Domvanalimab trial (NCT06727565) in Head and Neck Squamous Cell Carcinoma
SourceZimberelimab Phase 2 Results Expected
Primary completion for Zimberelimab trial (NCT06727565) in Head and Neck Squamous Cell Carcinoma
SourceTAF Phase 2 Results Expected
Primary completion for TAF trial (NCT02932150) in Chronic Hepatitis B
SourcePlacebo Phase 2 Results Expected
Primary completion for Placebo trial (NCT02932150) in Chronic Hepatitis B
SourceOptimized Background Regimen (OBR) Phase 2 Results Expected
Primary completion for Optimized Background Regimen (OBR) trial (NCT06749054) in HIV-1-infection
SourceOral Lenacapavir Phase 2 Results Expected
Primary completion for Oral Lenacapavir trial (NCT06749054) in HIV-1-infection
SourceSacituzumab Govitecan-hziy Phase 2 Results Expected
Primary completion for Sacituzumab Govitecan-hziy trial (NCT05119907) in Solid Tumor
Sourceanitocabtagene-autoleucel Phase 2 Results Expected
Primary completion for anitocabtagene-autoleucel trial (NCT05396885) in Multiple Myeloma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Trodelvy
Sacituzumab Govitecan
Triple-Negative Breast Cancer
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Cystic Fibrosis
ABC/DTG/3TC
HIV-1 Infection
Axicabtagene Ciloleucel
High-risk Large B-cell Lymphoma (LBCL)
ABC/3TC
HIV-1 Infection
Elvitegravir
HIV Infection
GS-4182
HIV-1-Infection
F/R/TAF
HIV-1 Infection
Stable Baseline Regimen
HIV-1-infection
Seladelpar 5 mg Capsule
Primary Biliary Cirrhosis
Remdesivir
COVID-19
Zidovudine
HIV Infections
Adefovir Dipivoxil for oral suspension, 2 mg/mL
Chronic Hepatitis B
Platinum-containing Salvage Chemotherapy
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tobramycin inhalation solution
Cystic Fibrosis
Lenacapavir Tablet
HIV Pre-exposure Prophylaxis
F/TAF
HIV-1 Infection
EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome
EFV/FTC/TDF
HIV
Subcutaneous Lenacapavir
HIV-1-infection
Metformin
Type 2 Diabetes Mellitus
AZLI 75 mg three times a day (TID)
Cystic Fibrosis
NRTIs
HIV-1 Infection
Adalimumab
Rheumatoid Arthritis
TAF
HBeAg-positive Chronic Hepatitis B
Docetaxel
Non-Small Cell Lung Cancer
RBV
Hepatitis C Virus Infection
Atripla
HIV
COBI
Acquired Immunodeficiency Syndrome
Adenosine
Coronary Artery Disease
Tobramycin Inhalation Solution (TIS)
Cystic Fibrosis
nab-Paclitaxel
Triple Negative Breast Cancer
PTM B/F/TAF
HIV-1-infection
B/F/TAF (Adult Strength)
HIV-1 Infection
FTC/RPV/TDF
HIV-1 Infection
E/C/F/TAF
HIV
Tenofovir disoproxil fumarate (TDF)
Hepatitis B Virus (HBV)
SOF
Hepatitis C
BIC/LEN FDC
HIV-1-infection
FTC/TDF
Chronic Hepatitis B
Oral Lenacapavir
HIV-1-infection
Ranolazine
Type 2 Diabetes Mellitus
AZLI
Cystic Fibrosis
Tenofovir DF
HIV Infections
B/F/TAF
HIV-1-infection
F/TDF
Pre-Exposure Prophylaxis of HIV-1 Infection
MBX-102
Type 2 Diabetes
Filgotinib
Ulcerative Colitis
Aztreonam for Inhalation Solution (AZLI)
Cystic Fibrosis
Idelalisib
Hodgkin Lymphoma
SOF/VEL
Hepatitis C Virus Infection
Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Peg-IFN
Hepatitis C
Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer
Cyclophosphamide
Relapsed/Refractory Follicular Lymphoma
ADV
Chronic Hepatitis B
Lenacapavir Injection
Pre-Exposure Prophylaxis of HIV Infection
Doxorubicin
Endometrial Cancer
AmBisome
Invasive Aspergillosis
Bendamustine
Chronic Lymphocytic Leukemia
DTG
HIV-1/HBV Co-Infection
Anitocabtagene Autoleucel
Multiple Myeloma
Liposomal amphotericin B
Invasive Fungal Disease
Andecaliximab
Gastric Adenocarcinoma
Leucovorin
Gastric Adenocarcinoma
Domvanalimab
Advanced Non-Small Cell Lung Cancer
Eribulin
Metastatic Breast Cancer
E/C/F/TDF
HIV
PI
HIV-1 Infection
TDF
Chronic Hepatitis B
LDV/SOF
Chronic Hepatitis C Virus
ambrisentan
Pulmonary Hypertension
Optimized Background Regimen (OBR)
HIV-1-infection
Eribulin Mesylate Injection
Metastatic Breast Cancer
Viread (tenofovir disoproxil fumarate)
HIV Infections
GS-1720
HIV-1-infection
AZLI 75 mg two times a day (BID)/three times a day (TID)
Cystic Fibrosis
MTX
Rheumatoid Arthritis
Cobicistat
Acquired Immune Deficiency Syndrome (AIDS)
SOF/VEL/VOX
Hepatitis C Virus Infection
NNRTI
Acquired Immunodeficiency Syndrome
Obeldesivir
COVID-19
PEG
Hepatitis C
Bictegravir
HIV-1-infection
Sofosbuvir
Hepatitis C, Chronic
E/C/F/TAF (Low Dose)
Acquired Immune Deficiency Syndrome (AIDS)
ISL/LEN
HIV-1-Infection
Carboplatin
Non-small Cell Lung Cancer
Bulevirtide
Chronic Hepatitis Delta
Darusentan
Hypertension
FTC
Chronic Hepatitis B
Seladelpar 10 mg
Primary Biliary Cholangitis
3rd ARV agent
HIV-1
Emtricitabine (FTC)
HIV Infections
DRV
HIV-1 Infection
Regadenoson
Coronary Artery Disease
ATV
HIV
FTC/RPV/TAF
HIV-1 Infection
Vinflunine
Locally Advanced or Metastatic Unresectable Urothelial Cancer
AZLI 75 mg three times daily (TID)
Cystic Fibrosis
3TC
HIV-1 Infection
zidovudine and lamivudine (Combivir®)
HIV Infections
Subcutaneous (SC) Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Lenacapavir
HIV Prevention
Magrolimab
Myelodysplastic Syndrome
Zimberelimab
Head and Neck Squamous Cell Carcinoma
Stribild
Acquired Immunodeficiency Syndrome
Sacituzumab Govitecan (SG)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Paclitaxel
Locally Advanced or Unresectable Metastatic Breast Cancer
Baseline DRV- containing ARV regimen
HIV-1
seladelpar 5-10 mg
Primary Biliary Cholangitis
RTV
Acquired Immunodeficiency Syndrome
Seladelpar
Primary Biliary Cholangitis
Current failing ARV regimen
HIV
Adefovir Dipivoxil (ADV)
Chronic Hepatitis B
MBX-8025 50 mg (Dose Escalation Period 1)
Homozygous Familial Hypercholesterolemia
Tirabrutinib
Chronic Lymphocytic Leukemia
MBX-2044
Type 2 Diabetes Mellitus
Cetuximab
Solid Tumor
GS-9451
Hepatitis C, Chronic
KTE-C19
Refractory Diffuse Large B Cell Lymphoma
Edecesertib
Cutaneous Lupus Erythematosus (CLE)
Ruxolitinib
Myelofibrosis
Hepatitis B virus (HBV) OAV Therapy
Chronic Hepatitis B
D/C/F/TAF
Acquired Immunodeficiency Syndrome
GS-9876
Rheumatoid Arthritis
BSF 208075
Pulmonary Hypertension
Semaglutide
Nonalcoholic Steatohepatitis
Tenofovir disoproxil fumarate
Chronic Hepatitis B
Tegobuvir (GS-9190)
Hepatitis C, Chronic
GS-4321
Chronic Hepatitis Delta
Pembrolizumab
Non-small Cell Lung Cancer
Remdesivir (RDV)
COVID-19
Indinavir sulfate
HIV Infections
Efavirenz
HIV Infections
Fludarabine
Relapsed or Refractory Large B-cell Lymphoma
Cidofovir
Cytomegalovirus Retinitis
Febuxostat
Gout
Hepatitis B Immunoglobulin (HBIg)
Chronic Hepatitis B
emtricitabine /tenofovir DF
Chronic Hepatitis B
90Y-hPAM4
Pancreatic Cancer
MBX-8025
Hyperlipidemia
Colchicine
Hyperuricemia
Arhalofenate
Hyperuricemia
radiolabeled epratuzumab
Non-Hodgkin's Lymphoma
Semaglutide (SEMA)
Nonalcoholic Steatohepatitis
veltuzumab
NHL
Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Chronic Hepatitis B
Abacavir
HIV
GS-9137 - A Novel HIV-1 Integrase Inhibitor
HIV
BIC
HIV-1 Infection
FIR
Nonalcoholic Steatohepatitis
Adefovir Dipivoxil
Hepatitis B
ISL
HIV-1 Infection
brexucabtagene autoleucel
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Tenofovir Alafenamide
Chronic Hepatitis B
anitocabtagene-autoleucel
Multiple Myeloma
KTE-X19
Relapsed/Refractory Mantle Cell Lymphoma
Nelfinavir mesylate
HIV Infections
SIM
Non-Alcoholic Steatohepatitis (NASH)
CILO
Nonalcoholic Steatohepatitis (NASH)
Pegasys®
Chronic Hepatitis C Infection
Avelumab
Metastatic Urothelial Cancer
Aztreonam for Inhalation (AI)
Cystic Fibrosis
Allopurinol
Gout
Tilpisertib Fosmecarbil
Ulcerative Colitis
VDV
Hepatitis C Virus Infection
Dronedarone
Atrial Fibrillation
IMMU-107 (hPAM4)
Pancreatic Cancer
FTI, AZLI
Cystic Fibrosis
VOX
Hepatitis C Virus Infection
SEL
Diabetic Kidney Disease
EFV
Hepatitis C
milatuzumab
Chronic Lymphocytic Lymphoma
tegobuvir capsule
Chronic Genotype 1a or 1b HCV Infection
Emtricitabine
HIV Infections
abacavir 300mg twice daily
Lipodystrophy
Tegobuvir
Hepatitis C, Chronic
Simtuzumab
Primary Sclerosing Cholangitis (PSC)
Ribavirin
Hepatitis C
Tecadenoson
Atrial Fibrillation
Brexucabtagene Autoleucel (KTE-X19)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
MBX-8025 2 mg Capsule
Primary Biliary Cirrhosis
OAV Regimen
Chronic HBV Infection
hA20-humanized anti-CD20 antibody
Non-Hodgkin's Lymphoma
MBX-2982
Diabetes
GS-1427
Ulcerative Colitis
GS-9190
HCV Infection
Eleclazine
Ventricular Arrhythmia
GS-9450
Nonalcoholic Steatohepatitis
GS-5806
Respiratory Syncytial Virus Infections
LDV
Chronic Hepatitis C Infection
GS-5885
Hepatitis C, Chronic
Gemcitabine
Pancreatic Cancer
Obinutuzumab
Chronic Lymphocytic Leukemia
90Y-hLL2
NHL
Vesatolimod
HIV-1-infection
VEL
Hepatitis C
Teropavimab
HIV Infection
Selonsertib
Alcoholic Hepatitis (AH)
EVG
HIV Infections
GS-5885 tablet
Hepatitis C, Chronic
hMN14 (labetuzumab)
Pancreatic Neoplasms
Abacavir sulfate
HIV Infections
Other approved antivirals
Chronic Hepatitis B
Lanraplenib
Lupus Membranous Nephropathy
Selgantolimod
Chronic Hepatitis B
GS-9674
Nonalcoholic Steatohepatitis (NASH)
Zimberelimab (ZIM)
Lung Cancer
GS-9669
Chronic HCV Infection
Presatovir
Respiratory Syncytial Virus
Arhalofenate 600 mg
Gout
Firsocostat
Nonalcoholic Steatohepatitis (NASH)
GS-9256
HCV Infection
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Pre-Exposure Prophylaxis of HIV Infection
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Trodelvy Sacituzumab Govitecan | Approved | Triple-Negative Breast Cancer | Fast TrackBreakthrough |
AZLI 75 mg two times a day (BID)/ three times a day (TID) | Phase 3 | Cystic Fibrosis | - |
ABC/DTG/3TC | Phase 3 | HIV-1 Infection | - |
Axicabtagene Ciloleucel | Phase 3 | High-risk Large B-cell Lymphoma (LBCL) | - |
ABC/3TC | Phase 3 | HIV-1 Infection | - |
Elvitegravir | Phase 3 | HIV Infection | - |
GS-4182 | Phase 3 | HIV-1-Infection | - |
F/R/TAF | Phase 3 | HIV-1 Infection | - |
Stable Baseline Regimen | Phase 3 | HIV-1-infection | - |
Seladelpar 5 mg Capsule | Phase 3 | Primary Biliary Cirrhosis | - |
Remdesivir | Phase 3 | COVID-19 | - |
Zidovudine | Phase 3 | HIV Infections | - |
Adefovir Dipivoxil for oral suspension, 2 mg/mL | Phase 3 | Chronic Hepatitis B | - |
Platinum-containing Salvage Chemotherapy | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | - |
Tobramycin inhalation solution | Phase 3 | Cystic Fibrosis | - |
Lenacapavir Tablet | Phase 3 | HIV Pre-exposure Prophylaxis | - |
F/TAF | Phase 3 | HIV-1 Infection | - |
EVG/COBI/FTC/TDF | Phase 3 | Acquired Immunodeficiency Syndrome | - |
EFV/FTC/TDF | Phase 3 | HIV | - |
Subcutaneous Lenacapavir | Phase 3 | HIV-1-infection | - |
Metformin | Phase 3 | Type 2 Diabetes Mellitus | - |
AZLI 75 mg three times a day (TID) | Phase 3 | Cystic Fibrosis | - |
NRTIs | Phase 3 | HIV-1 Infection | - |
Adalimumab | Phase 3 | Rheumatoid Arthritis | - |
TAF | Phase 3 | HBeAg-positive Chronic Hepatitis B | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - |
RBV | Phase 3 | Hepatitis C Virus Infection | - |
Atripla | Phase 3 | HIV | - |
COBI | Phase 3 | Acquired Immunodeficiency Syndrome | - |
Adenosine | Phase 3 | Coronary Artery Disease | - |
Tobramycin Inhalation Solution (TIS) | Phase 3 | Cystic Fibrosis | - |
nab-Paclitaxel | Phase 3 | Triple Negative Breast Cancer | - |
PTM B/F/TAF | Phase 3 | HIV-1-infection | - |
B/F/TAF (Adult Strength) | Phase 3 | HIV-1 Infection | - |
FTC/RPV/TDF | Phase 3 | HIV-1 Infection | - |
E/C/F/TAF | Phase 3 | HIV | - |
Tenofovir disoproxil fumarate (TDF) | Phase 3 | Hepatitis B Virus (HBV) | - |
SOF | Phase 3 | Hepatitis C | - |
BIC/LEN FDC | Phase 3 | HIV-1-infection | - |
FTC/TDF | Phase 3 | Chronic Hepatitis B | - |
Oral Lenacapavir | Phase 3 | HIV-1-infection | - |
Ranolazine | Phase 3 | Type 2 Diabetes Mellitus | - |
AZLI | Phase 3 | Cystic Fibrosis | - |
Tenofovir DF | Phase 3 | HIV Infections | - |
B/F/TAF | Phase 3 | HIV-1-infection | - |
F/TDF | Phase 3 | Pre-Exposure Prophylaxis of HIV-1 Infection | - |
MBX-102 | Phase 3 | Type 2 Diabetes | - |
Filgotinib | Phase 3 | Ulcerative Colitis | - |
Aztreonam for Inhalation Solution (AZLI) | Phase 3 | Cystic Fibrosis | - |
Idelalisib | Phase 3 | Hodgkin Lymphoma | - |
SOF/VEL | Phase 3 | Hepatitis C Virus Infection | - |
Sacituzumab govitecan-hziy (SG) | Phase 3 | Triple Negative Breast Cancer | - |
Peg-IFN | Phase 3 | Hepatitis C | - |
Sacituzumab Govitecan-hziy | Phase 3 | Triple Negative Breast Cancer | - |
Cyclophosphamide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - |
ADV | Phase 3 | Chronic Hepatitis B | - |
Lenacapavir Injection | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - |
Doxorubicin | Phase 3 | Endometrial Cancer | - |
AmBisome | Phase 3 | Invasive Aspergillosis | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia | - |
DTG | Phase 3 | HIV-1/HBV Co-Infection | - |
Anitocabtagene Autoleucel | Phase 3 | Multiple Myeloma | - |
Liposomal amphotericin B | Phase 3 | Invasive Fungal Disease | - |
Andecaliximab | Phase 3 | Gastric Adenocarcinoma | - |
Leucovorin | Phase 3 | Gastric Adenocarcinoma | - |
Domvanalimab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - |
Eribulin | Phase 3 | Metastatic Breast Cancer | - |
E/C/F/TDF | Phase 3 | HIV | - |
PI | Phase 3 | HIV-1 Infection | - |
TDF | Phase 3 | Chronic Hepatitis B | - |
LDV/SOF | Phase 3 | Chronic Hepatitis C Virus | - |
ambrisentan | Phase 3 | Pulmonary Hypertension | - |
Optimized Background Regimen (OBR) | Phase 3 | HIV-1-infection | - |
Eribulin Mesylate Injection | Phase 3 | Metastatic Breast Cancer | - |
Viread (tenofovir disoproxil fumarate) | Phase 3 | HIV Infections | - |
GS-1720 | Phase 3 | HIV-1-infection | - |
AZLI 75 mg two times a day (BID)/three times a day (TID) | Phase 3 | Cystic Fibrosis | - |
MTX | Phase 3 | Rheumatoid Arthritis | - |
Cobicistat | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - |
SOF/VEL/VOX | Phase 3 | Hepatitis C Virus Infection | - |
NNRTI | Phase 3 | Acquired Immunodeficiency Syndrome | - |
Obeldesivir | Phase 3 | COVID-19 | - |
PEG | Phase 3 | Hepatitis C | - |
Bictegravir | Phase 3 | HIV-1-infection | - |
Sofosbuvir | Phase 3 | Hepatitis C, Chronic | - |
E/C/F/TAF (Low Dose) | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - |
ISL/LEN | Phase 3 | HIV-1-Infection | - |
Carboplatin | Phase 3 | Non-small Cell Lung Cancer | - |
Bulevirtide | Phase 3 | Chronic Hepatitis Delta | - |
Darusentan | Phase 3 | Hypertension | - |
FTC | Phase 3 | Chronic Hepatitis B | - |
Seladelpar 10 mg | Phase 3 | Primary Biliary Cholangitis | - |
3rd ARV agent | Phase 3 | HIV-1 | - |
Emtricitabine (FTC) | Phase 3 | HIV Infections | - |
DRV | Phase 3 | HIV-1 Infection | - |
Regadenoson | Phase 3 | Coronary Artery Disease | - |
ATV | Phase 3 | HIV | - |
FTC/RPV/TAF | Phase 3 | HIV-1 Infection | - |
Vinflunine | Phase 3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | - |
AZLI 75 mg three times daily (TID) | Phase 3 | Cystic Fibrosis | - |
3TC | Phase 3 | HIV-1 Infection | - |
zidovudine and lamivudine (Combivir®) | Phase 3 | HIV Infections | - |
Subcutaneous (SC) Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - |
Lenacapavir | Phase 3 | HIV Prevention | Fast TrackBreakthrough |
Magrolimab | Phase 3 | Myelodysplastic Syndrome | OrphanFast TrackBreakthrough |
Zimberelimab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - |
Stribild | Phase 3 | Acquired Immunodeficiency Syndrome | - |
Sacituzumab Govitecan (SG) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - |
Paclitaxel | Phase 3 | Locally Advanced or Unresectable Metastatic Breast Cancer | - |
Baseline DRV- containing ARV regimen | Phase 3 | HIV-1 | - |
seladelpar 5-10 mg | Phase 3 | Primary Biliary Cholangitis | - |
RTV | Phase 3 | Acquired Immunodeficiency Syndrome | - |
Seladelpar | Phase 3 | Primary Biliary Cholangitis | - |
Current failing ARV regimen | Phase 3 | HIV | - |
Adefovir Dipivoxil (ADV) | Phase 3 | Chronic Hepatitis B | - |
MBX-8025 50 mg (Dose Escalation Period 1) | Phase 2 | Homozygous Familial Hypercholesterolemia | - |
Tirabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - |
MBX-2044 | Phase 2 | Type 2 Diabetes Mellitus | - |
Cetuximab | Phase 2 | Solid Tumor | - |
GS-9451 | Phase 2 | Hepatitis C, Chronic | - |
KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma | - |
Edecesertib | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | - |
Ruxolitinib | Phase 2 | Myelofibrosis | - |
Hepatitis B virus (HBV) OAV Therapy | Phase 2 | Chronic Hepatitis B | - |
D/C/F/TAF | Phase 2 | Acquired Immunodeficiency Syndrome | - |
GS-9876 | Phase 2 | Rheumatoid Arthritis | - |
BSF 208075 | Phase 2 | Pulmonary Hypertension | - |
Semaglutide | Phase 2 | Nonalcoholic Steatohepatitis | - |
Tenofovir disoproxil fumarate | Phase 2 | Chronic Hepatitis B | - |
Tegobuvir (GS-9190) | Phase 2 | Hepatitis C, Chronic | - |
GS-4321 | Phase 2 | Chronic Hepatitis Delta | - |
Pembrolizumab | Phase 2 | Non-small Cell Lung Cancer | - |
Remdesivir (RDV) | Phase 2 | COVID-19 | - |
Indinavir sulfate | Phase 2 | HIV Infections | - |
Efavirenz | Phase 2 | HIV Infections | - |
Fludarabine | Phase 2 | Relapsed or Refractory Large B-cell Lymphoma | - |
Cidofovir | Phase 2 | Cytomegalovirus Retinitis | - |
Febuxostat | Phase 2 | Gout | - |
Hepatitis B Immunoglobulin (HBIg) | Phase 2 | Chronic Hepatitis B | - |
emtricitabine /tenofovir DF | Phase 2 | Chronic Hepatitis B | - |
90Y-hPAM4 | Phase 2 | Pancreatic Cancer | - |
MBX-8025 | Phase 2 | Hyperlipidemia | - |
Colchicine | Phase 2 | Hyperuricemia | - |
Arhalofenate | Phase 2 | Hyperuricemia | - |
radiolabeled epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - |
Semaglutide (SEMA) | Phase 2 | Nonalcoholic Steatohepatitis | - |
veltuzumab | Phase 2 | NHL | - |
Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Phase 2 | Chronic Hepatitis B | - |
Abacavir | Phase 2 | HIV | - |
GS-9137 - A Novel HIV-1 Integrase Inhibitor | Phase 2 | HIV | - |
BIC | Phase 2 | HIV-1 Infection | - |
FIR | Phase 2 | Nonalcoholic Steatohepatitis | - |
Adefovir Dipivoxil | Phase 2 | Hepatitis B | - |
ISL | Phase 2 | HIV-1 Infection | - |
brexucabtagene autoleucel | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - |
Tenofovir Alafenamide | Phase 2 | Chronic Hepatitis B | - |
anitocabtagene-autoleucel | Phase 2 | Multiple Myeloma | - |
KTE-X19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - |
SIM | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - |
CILO | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - |
Pegasys® | Phase 2 | Chronic Hepatitis C Infection | - |
Avelumab | Phase 2 | Metastatic Urothelial Cancer | - |
Aztreonam for Inhalation (AI) | Phase 2 | Cystic Fibrosis | - |
Allopurinol | Phase 2 | Gout | - |
Tilpisertib Fosmecarbil | Phase 2 | Ulcerative Colitis | - |
VDV | Phase 2 | Hepatitis C Virus Infection | - |
Dronedarone | Phase 2 | Atrial Fibrillation | - |
IMMU-107 (hPAM4) | Phase 2 | Pancreatic Cancer | - |
FTI, AZLI | Phase 2 | Cystic Fibrosis | - |
VOX | Phase 2 | Hepatitis C Virus Infection | - |
SEL | Phase 2 | Diabetic Kidney Disease | - |
EFV | Phase 2 | Hepatitis C | - |
milatuzumab | Phase 2 | Chronic Lymphocytic Lymphoma | - |
tegobuvir capsule | Phase 2 | Chronic Genotype 1a or 1b HCV Infection | - |
Emtricitabine | Phase 2 | HIV Infections | - |
abacavir 300mg twice daily | Phase 2 | Lipodystrophy | - |
Tegobuvir | Phase 2 | Hepatitis C, Chronic | - |
Simtuzumab | Phase 2 | Primary Sclerosing Cholangitis (PSC) | - |
Ribavirin | Phase 2 | Hepatitis C | - |
Tecadenoson | Phase 2 | Atrial Fibrillation | - |
Brexucabtagene Autoleucel (KTE-X19) | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - |
MBX-8025 2 mg Capsule | Phase 2 | Primary Biliary Cirrhosis | - |
OAV Regimen | Phase 2 | Chronic HBV Infection | - |
hA20-humanized anti-CD20 antibody | Phase 2 | Non-Hodgkin's Lymphoma | - |
MBX-2982 | Phase 2 | Diabetes | - |
GS-1427 | Phase 2 | Ulcerative Colitis | - |
GS-9190 | Phase 2 | HCV Infection | - |
Eleclazine | Phase 2 | Ventricular Arrhythmia | - |
GS-9450 | Phase 2 | Nonalcoholic Steatohepatitis | - |
GS-5806 | Phase 2 | Respiratory Syncytial Virus Infections | - |
LDV | Phase 2 | Chronic Hepatitis C Infection | - |
GS-5885 | Phase 2 | Hepatitis C, Chronic | - |
Gemcitabine | Phase 2 | Pancreatic Cancer | - |
Obinutuzumab | Phase 2 | Chronic Lymphocytic Leukemia | - |
90Y-hLL2 | Phase 2 | NHL | - |
Vesatolimod | Phase 2 | HIV-1-infection | - |
VEL | Phase 2 | Hepatitis C | - |
Teropavimab | Phase 2 | HIV Infection | - |
Selonsertib | Phase 2 | Alcoholic Hepatitis (AH) | - |
EVG | Phase 2 | HIV Infections | - |
GS-5885 tablet | Phase 2 | Hepatitis C, Chronic | - |
hMN14 (labetuzumab) | Phase 2 | Pancreatic Neoplasms | - |
Abacavir sulfate | Phase 2 | HIV Infections | - |
Other approved antivirals | Phase 2 | Chronic Hepatitis B | - |
Lanraplenib | Phase 2 | Lupus Membranous Nephropathy | - |
Selgantolimod | Phase 2 | Chronic Hepatitis B | - |
GS-9674 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - |
Zimberelimab (ZIM) | Phase 2 | Lung Cancer | - |
GS-9669 | Phase 2 | Chronic HCV Infection | - |
Presatovir | Phase 2 | Respiratory Syncytial Virus | - |
Arhalofenate 600 mg | Phase 2 | Gout | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - |
GS-9256 | Phase 2 | HCV Infection | - |
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Phase 2 | Pre-Exposure Prophylaxis of HIV Infection | - |
Regulatory & News
Approvals, filings, and latest developments